Aztreonam is a monobactam antibacterial with enhanced beta-lactamase stability, targeted to aerobic Gram-negative bacteria, including Pseudomonas spp. Cayston is administered by inhalation using a nebulizer.

Pre-Authorization Criteria: cystic fibrosis (CF) patients over 7 years old with known infection with Pseudomonas aeruginosa

Dosing: 75 mg three times a day for 28 days via nebulizer, after pre-treatment with a bronchodilator

How Supplied: 75 mg in single-use vial to be reconstituted with 1 mL diluent

Contraindications/Warnings: known allergy to aztreonam

Major Adverse Reactions: cough; acute bronchospasm; rebound decrease in FEV1 after course of therapy

Major Drug Interactions: none described

REFERENCES


**Revision History:**

Date Approved by P&T Committee: 4/22/14  
Date Reviewed/Updated: 2/17/15 by C. Sanders, MD; R. Sterling, MD  
Date Approved by P&T Committee: 1/26/16  
Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD  
Date Approved by P&T Committee: 1/24/17  
Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD; R. Sterling, MD  
Date Approved by P&T Committee: 1/23/18

<table>
<thead>
<tr>
<th>Revision Date</th>
<th>Content Revised (Yes/No)</th>
<th>Contributors</th>
<th>Review/Revision Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/24/17</td>
<td>No</td>
<td>Catherine Sanders, MD;</td>
<td>Annual review</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Robert Sterling, MD</td>
<td></td>
</tr>
<tr>
<td>1/23/18</td>
<td>No</td>
<td>Catherine Sanders, MD;</td>
<td>Annual review</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Robert Sterling, MD</td>
<td></td>
</tr>
</tbody>
</table>